NCT00082199

Brief Summary

The purpose of this clinical research study is to learn whether subjects treated with aripiprazole are able to abstain from alcohol use for a greater number of days than subjects treated with placebo. The safety of using aripiprazole will also be studied.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Apr 2004

Geographic Reach
1 country

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2004

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

April 30, 2004

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 4, 2004

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2005

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2005

Completed
Last Updated

November 11, 2013

Status Verified

July 1, 2008

Enrollment Period

1.3 years

First QC Date

April 30, 2004

Last Update Submit

November 7, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assessment of abstinence from the consumption of alcohol during the study

Secondary Outcomes (1)

  • Assessment of alcohol use during the study and behavioral measures of substance abuse an dependence

Study Arms (2)

A1

ACTIVE COMPARATOR
Drug: Aripiprazole

A2

PLACEBO COMPARATOR
Drug: Placebo

Interventions

Tablets, Oral, 2-30mg, Once daily, 12 weeks.

Also known as: Abilify
A1

Tablets, Oral, Once daily, 12 weeks.

A2

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with a diagnosis of alcohol dependence who want to stop using alcohol will be considered for the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Local Institution

Farmington, Connecticut, United States

Location

Local Institution

New Haven, Connecticut, United States

Location

Local Institution

Indianapolis, Indiana, United States

Location

Local Institution

Boston, Massachusetts, United States

Location

Local Institution

New York, New York, United States

Location

Local Institution

Rochester, New York, United States

Location

Local Institution

Chapel Hill, North Carolina, United States

Location

Local Institution

Philadelphia, Pennsylvania, United States

Location

Local Institution

Providence, Rhode Island, United States

Location

Local Institution

Charleston, South Carolina, United States

Location

Local Institution

Dallas, Texas, United States

Location

Local Institution

Houston, Texas, United States

Location

Local Institution

Charlottesville, Virginia, United States

Location

Local Institution

Milwaukee, Wisconsin, United States

Location

Related Publications (1)

  • Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008 Feb;28(1):5-12. doi: 10.1097/jcp.0b013e3181602fd4.

MeSH Terms

Conditions

Alcoholism

Interventions

Aripiprazole

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Bristol-Myers Squibb

    Bristol-Myers Squibb

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 30, 2004

First Posted

May 4, 2004

Study Start

April 1, 2004

Primary Completion

August 1, 2005

Study Completion

August 1, 2005

Last Updated

November 11, 2013

Record last verified: 2008-07

Locations